ATLANTA--(BUSINESS WIRE)-- Inhibitex, Inc. (Nasdaq: INHX), today announced that Russell Plumb, president and chief executive officer, will present an overview of the Company and an update of its pipeline of differentiated anti-infective compounds at the ROTH 23rd Annual Growth Stock Conference on March 15, 2011 at 2:30 PM (PST). The conference is being held at the Ritz Carlton Laguna Niguel in Dana Point, California.
Inhibitex, Inc., is a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Company’s clinical-stage pipeline includes FV-100, a nucleoside inhibitor in Phase II for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in Phase 1b for the treatment of chronic hepatitis C infections. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM® protein platform to Pfizer for the development of a staphylococcal vaccine, which is currently being evaluated in a Phase 1 clinical trial. For additional information about the Company, please visit www.inhibitex.com.
Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex, Inc.
KEYWORDS: United States North America California Georgia
INDUSTRY KEYWORDS: Health Biotechnology Infectious Diseases Pharmaceutical Research Science